Fernández-Miranda Juan J, Díaz-Fernández Silvia, De Berardis Domenico, López-Muñoz Francisco
Asturian Mental Health Service Área V-Servicio de Salud del Principado de Asturias (SESPA), 33211 Gijón, Spain.
Asturian Institute on Health Research (ISPA), 33011 Oviedo, Spain.
J Clin Med. 2021 Apr 1;10(7):1408. doi: 10.3390/jcm10071408.
Paliperidone palmitate every three months (PP3M) is expected to facilitate patient's treatment compliance and satisfaction. The objective here was to compare PP3M treatment compliance and satisfaction, effectiveness and tolerability, with paliperidone palmitate-monthly (PP1M) in patients with severe schizophrenia. A 24-month prospective, open-label study of patients with severe schizophrenia treated with PP3M after at least 2 years of stabilization with PP1M ( = 84) was carried out. Treatment satisfaction was assessed with the Treatment Satisfaction Questionnaire for Medication (TSQM) and with a Visual Analogue Scale (VAS). Effectiveness was measured with psychiatric hospital admissions and the Clinical Global Impression-Severity (CGI-S) scale. Tolerability assessments included laboratory tests, weight and adverse effects. Reasons for treatment discontinuation were recorded. CGI-S significantly improved after 24 months. Three patients changed back to PP1M due to adverse effects, and four were hospitalized. There were neither abandoning nor significant changes in weight or biological parameters, and lower incidence of side effects, with PP3M treatment. TSQM and VAS scales increased. No differences were found related to doses. Apart from somewhat improvement in treatment adherence, effectiveness, and tolerability, patients with severe schizophrenia lengthy treated with PP1M showed more satisfaction with PP3M, even those who needed high doses to get clinical stabilization.
棕榈酸帕利哌酮每三个月一次（PP3M）有望提高患者的治疗依从性和满意度。本研究的目的是比较PP3M与每月一次棕榈酸帕利哌酮（PP1M）在重度精神分裂症患者中的治疗依从性、满意度、有效性和耐受性。对至少经过2年PP1M稳定治疗（n = 84）后接受PP3M治疗的重度精神分裂症患者进行了一项为期24个月的前瞻性开放标签研究。使用药物治疗满意度问卷（TSQM）和视觉模拟量表（VAS）评估治疗满意度。通过精神病院住院次数和临床总体印象-严重程度（CGI-S）量表衡量有效性。耐受性评估包括实验室检查、体重和不良反应。记录治疗中断的原因。24个月后CGI-S显著改善。3例患者因不良反应换回PP1M，4例患者住院。PP3M治疗期间，体重或生物学参数既无下降也无显著变化，副作用发生率较低。TSQM和VAS量表得分增加。未发现与剂量相关的差异。除了在治疗依从性、有效性和耐受性方面有所改善外，长期接受PP1M治疗的重度精神分裂症患者对PP3M更满意，即使是那些需要高剂量才能达到临床稳定的患者。
